While many companies operate in the biologic space, BSP Biologics has advanced this field through the development of Bio-Serum Particles (BSPs). Derived from a patient's own blood, BSPs are processed to yield a complex profile of biologically active components, including proteins, lipids, regulatory RNAs, cytokines, and other signaling molecules associated with cellular communication.
In fertility and IVF applications, BSPs are being studied for their potential to support oocyte and endometrial microenvironments, as well as biological signaling processes relevant to embryo–maternal interactions.
Beyond assisted reproduction, BSPs are also being explored across broader OBGYN applications, including conditions where tissue microenvironment, inflammation, and cellular signaling play a role, such as endometriosis, PCOS, and menopause-associated changes.
Bio-Serum Particles represent a cell-free, autologous biologic approach designed to support physiologic balance within reproductive and gynecologic systems.
BSP Biologics™ operates in alignment with FDA 21 CFR Part 1271 frameworks governing human cellular and tissue-based products (HCT/Ps). Our autologous platforms are utilized within physician-directed care models and IRB-supported clinical programs, with a focus on safety, traceability, and regulatory awareness.
Comprehensive characterization, where applicable, includes:
Each BSP preparation undergoes defined quality control assessments, where applicable, prior to clinical or research use. Release criteria are designed to support consistency, traceability, and controlled handling of patient-derived biologic material.
Quality parameters may include:
All processes are conducted within controlled environments and aligned with internal standard operating procedures and applicable regulatory frameworks.
Our advanced platform leverages each patient's own biology to support fertility treatments with the highest standards of safety and compliance. Because every treatment is derived exclusively from the patient's own biologic sample, there is no risk of immunogenicity. Each therapy is uniquely tailored to the individual, maximizing compatibility and minimizing risk.
Because Bio-Serum Particles are cell-free and derived from the patient's own blood, they are biologically compatible and do not trigger immune rejection. Unlike stem cell therapy, which uses live cells, BSPs are completely cell-free, providing a unique therapeutic option for reproductive medicine.